November 2025 is here, and if you’re serious about making money, you cannot ignore what’s happening right now. Three companies are sitting at the heart of the biggest wealth creation wave of the decade—and no, this isn’t hype. We’re talking real earnings, real contracts, and unstoppable momentum.
💡 Fun fact: Since 1927, the S&P 500 has gone up 79% of all Novembers. But when October ends positive, like it did in 2025, November jumps to a 92% success rate—with average returns of 1.5%! The clock is ticking, and the window is closing fast.
Here’s what you need to know about the three stocks that could explode before year-end:
1️⃣ Applied Digital – The AI Infrastructure Wild Card
This is the stock for aggressive growth seekers. Analysts expected $50–52M revenue in Q1 FY2026. Applied Digital delivered $64.2M, up 84% YoY.
$26.3M came from tenant fitout services, building Core Weeav’s Polaris Forge—the backbone of next-gen AI.
$37.9M came from data center hosting, growing at 9% YoY.
💥 Expansion alert: Polaris Forge 1 just jumped from 250MW → 400MW, raising contracted revenue potential to $11B from one customer alone. Polaris Forge 2 is already under construction, with more deals in the pipeline.
Yes, the stock isn’t profitable yet. But they just secured $362.5M in financing, giving them over $476M in liquidity—enough to dominate AI infrastructure. High-risk, yes. High-reward? Absolutely.
2️⃣ Broadcom – The AI Chip Giant
If Applied Digital is the wild card, Broadcom is the rock-solid powerhouse.
Q3 FY2025 revenue: $16B, beating estimates with 22% YoY growth.
AI semiconductor revenue: $5.2B, up 63% YoY.
Broadcom isn’t chasing trends—they are the trend. With a $110B backlog, multi-year deals with OpenAI, Alphabet, and Meta, and 11 consecutive quarters of AI growth, this stock is a core holding for serious investors.
Free cash flow: $7B
Gross margin: 78.4%
Operating margin: 65.5%
Yes, P/E is high at 94.47—but when you’re sitting on $110B of multi-year revenue visibility, the market pays for certainty.
3️⃣ Eli Lilly – Pharma’s Profit Machine
Shifting gears from tech to healthcare dominance: Eli Lilly is crushing it in diabetes and obesity treatments.
Q3 2025 revenue: $17.6B, up 54% YoY
Net income: $5.58B
Breakout products:
Mounjaro (diabetes): $6.52B, +109% YoY
Zepbound (obesity): $3.59B, +184% YoY
That’s 57% of total revenue from just two drugs. And management isn’t stopping—they’re investing $11.2B in new manufacturing capacity. Stability, growth, and profitability all in one.
✅ How to Think About These Stocks
High-risk, high-reward: Applied Digital
Core, quality growth: Broadcom
Stable, profitable, growing: Eli Lilly
With November’s historical seasonal edge, macro trends, and AI/healthcare momentum, the timing is perfect to deploy capital strategically.
🔥 Don’t just watch—take action now! If you want a simple way to invest in these opportunities, check out moomoo. You can easily buy ETFs and stocks like these in minutes: Invest with moomoo here
💬 Which of these three stocks are you most excited about? Comment below and let’s talk!
#stocks #investing #AI #healthcare #Broadcom #AppliedDigital #EliLilly #moomoo #wealthcreation #November2025 #ETF
